Stanford University’s Faculty Senate today approved the creation of what officials believe is the first PhD program devoted solely to stem cell science in the nation and, perhaps, the world. The new doctoral program in stem cell biology and regenerative medicine is also the first interdisciplinary doctoral program created by the School of Medicine in recent years.
School officials say the fact that the university is taking the rare step of creating a new doctoral program acknowledges the growing importance of stem cell research in the realm of biomedical science. The senate’s initial approval
Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell science at last weekend’s Association of Health Care Journalism 2015 conference.
“There’s an inherent flaw in our system,” said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. “Companies are driven by the desire for profits rather than the desire to find the best therapy, and they often give up on discoveries too early.”
Even Superman needed to retire to a phone booth for a quick change. But now scientists at the Stanford University School of Medicine have succeeded in the ultimate switch: transforming mouse skin cells in a laboratory dish directly into functional nerve cells with the application of just three genes. The cells make the change without first becoming a pluripotent type of stem cell — a step long thought to be required for cells to acquire new identities.
The finding could revolutionize the future of human stem cell therapy and recast our understanding of how cells choose and maintain their specialties
SANTIAGO, Dominican Republic (CNN) — This Caribbean city already known for cigars, furniture, chocolate and coffee may become a magnet for Americans seeking controversial stem cell therapy for life-threatening illnesses if a Florida cardiologist has his way.
The Food and Drug Administration has not approved this stem cell therapy in the United States because no clinical trials to prove its effectiveness have been done. But Dr. Zannos Grekos says his company, Regenocyte Therapeutic, has successfully used adult stem cells to treat patients with heart and lung disease.
Grekos said he and his associates draw blood from a patient in Florida and
Researchers at the Stanford Institute for Stem Cell Biology and Regenerative Medicine and the Sackler School of Medicine in Israel have shown how the kidneys constantly grow and have surprising ability to regenerate themselves, overturning decades of accepted wisdom that such regeneration didn’t happen. It also opens a path toward new ways of repairing and even growing kidneys.
“These are basic findings that have direct implications for kidney disease and kidney regeneration,” says Yuval Rinkevich, PhD, the lead author of the paper and a postdoctoral scholar at the institute.
The findings were published online May 15 in Cell Reports.